美股行情約 15 分鐘延遲,僅供參考
LLY禮來

醫療 · 製藥

$1347.11-0.30%

最近行情 · 2026/11/22 05:00(北京時間)說明

禮來深度研究

瞭解本期變化、關鍵問題與接下來值得關注的事項。

最近檢查公告:2026/11/21 21:14:50(北京時間)。

財務資料與報告期間

財務摘要 · 生物科技與醫藥研發

單季度資料截至 2026-09-30 · 披露 2026-10-29

內容更新 2026-11-08 · 最近核驗 2026-11-16

超過日常核驗視窗,以下保留上次可用版本。

本期淨利非負;是否具有持續性,還需要結合收入來源、現金流和一次性專案核查。

營業收入
243.97億美元
2026-07-01 至 2026-09-30 · USD
淨利
64.51億美元
2026-07-01 至 2026-09-30 · USD
現金及現金等價物
48.85億美元
截至 2026-09-30 · USD
總資產
1,480.72億美元
截至 2026-09-30 · USD
歸屬母公司股東權益
402.71億美元
截至 2026-09-30 · USD

接下來關注什麼

  • 核對臨床進度、監管節點與專案失敗風險;研發支出不能代替療效證據。
  • 核對可用現金、融資約束與實際資金消耗,不能從單期虧損直接推算存續月份。
資料說明與暫缺專案
  • 經營現金流未取得本期同口徑資料,不使用舊期替代。
  • 總負債未取得本期同口徑資料,不使用舊期替代。
  • 現金流累計數未直接當作單季度;缺少可核對的單季值時留空。
  • 本頁提供財務摘要,詳細業務分析暫未提供。
最近定期披露與核對依據

披露日期不等於經營事件發生日;定期披露列表不代表已解釋全部重大事項。

返回公司概覽 →
新財報資料期 2026-09-30 · 研究更新 2026-10-29

營業收入 244億美元;較前期變化 6.2%

毛利率 83.88%;較前期變化 -1.9 個百分點

接下來關注:Mounjaro + Zepbound 合計季度銷售額

本期財務證據 · 2026-09-30

LLY:連續季度變化與現金流拆解

以下為已釋出資料的規則比較,不是人工研究核查。公司整體資料不能替代產品、地區或客戶指標;待驗證不等於投資邏輯未變。

連續季度財務對照
指標FY2026 Q3FY2026 Q2環比
營業收入243.97億美元229.74億美元+6.2%
經營現金流113.97億美元106.9億美元+6.6%

橫向滑動表格,檢視上季數值和環比變化。

現金流變化如何拆解

缺少連續季度的現金流欄位,暫不計算現金流變化歸因。

關鍵研究問題

GLP-1 產能擴張速度(供給是否跟上需求)

僅有間接線索

資料截至 2026-09-30

間接證據:本期營收變動 6.2%,毛利率變動 -1.9 個百分點。該結果只描述“產品放量質量”,不能單獨驗證當前研究變數,因此不輸出積極或負面結論。

產品放量質量:營收 6.2%;毛利率變動 -1.9 個百分點

繼續關注:同一產品的出貨、交付、產能或量產里程碑

暫未列出足以直接回答此問題的依據。

檢視依據與尚未確認的問題

僅憑公司整體收入或毛利率尚不能回答此問題。

間接線索 · 3 份檔案

客戶與供應鏈 · 10-Q 審閱文件原文 · 3 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
客戶與供應鏈 · 10-Q 審閱文件原文 · 4 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
客戶與供應鏈 · 10-Q 審閱文件原文 · 1 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

背景資料 · 12 份檔案

10-Q(提交於 2026-10-29) · 13 條摘錄閱讀原文 ↗
  • 2026 Q3:營收 24.40 十億美元,毛利率 83.88%,自由現金流 未披露。
  • LLY 於 2026-10-29 提交 10-Q:截至 2026-09-30 的定期報告。
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • Acquired in-process research and development 4,181 656 7,541 2,381
  • Acquired in-process research and development 7,541 2,381
  • We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
  • We have a license agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • Acquisition date June 25, 2026 June 24, 2026 March 4, 2026
10-Q(提交於 2026-08-05) · 12 條摘錄閱讀原文 ↗
  • 2026 Q2:營收 22.97 十億美元,毛利率 85.78%,自由現金流 未披露。
  • LLY 於 2026-08-05 提交 10-Q:截至 2026-06-30 的定期報告。
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • Acquired in-process research and development 2,776 154 3,360 1,726
  • Acquired in-process research and development 3,360 1,726
  • We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
  • We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
8-K 原始檔案 · 1 條摘錄閱讀原文 ↗
  • LLY 於 2026-10-29 提交 8-K:經營業績與財務狀況、財務報表與附件。
SCHEDULE 13D 原始檔案 · 5 條摘錄閱讀原文 ↗
  • LLY 於 2026-10-16 提交 SCHEDULE 13D:股東行動。
  • If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
  • The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.
  • The funds used by the Reporting Person to acquire the Common Stock purchased in the IPO consisted of cash on hand.
  • The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.
8-K 原始檔案 · 1 條摘錄閱讀原文 ↗
  • LLY 於 2026-08-05 提交 8-K:經營業績與財務狀況、財務報表與附件。
併購交易 · SCHEDULE 13D 審閱文件原文 · 4 條摘錄閱讀原文 ↗
  • If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
  • The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.
  • The funds used by the Reporting Person to acquire the Promissory Note and the Common Stock purchased in the IPO consisted of cash on hand.
  • The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.
訴訟進展 · 10-Q 審閱文件原文 · 13 條摘錄閱讀原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of March 31, 2026, we have the right to receive up to $ 660 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
  • We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
  • We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • In March 2026, we acquired all shares of Ventyx Biosciences, Inc. (Ventyx) for a purchase price of $ 14.00 per share in cash (or an aggregate of $ 1.1 billion, net of cash acquired).
  • Our access to information was limited prior to this acquisition.
訴訟進展 · 10-K 審閱文件原文 · 14 條摘錄閱讀原文 ↗
  • This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
  • We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.
  • See, for examples, Item 1A, "Risk Factors—Risks Related to Our Operations—Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could result in material harm to our business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."
  • A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.
  • The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.
  • Some of our products are subject to significant license and collaboration agreements.
  • For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 3: Collaborations and Other Arrangements."
  • The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.
  • Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.
  • For more information on patent challenges and litigation involving our intellectual property rights, see Item 1A, "Risk Factors—Risks Related to Our Intellectual Property—Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected" and Item 8, "Financial Statements and Supplementary Data—Note 16: Contingencies."
訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄閱讀原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Acquired in-process research and development (Note 3) 655.7 2,826.4 2,381.2 3,091.2
  • (1) As of September 30, 2025, there was $ 12.40 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
  • Acquired in-process research and development 2,381.2 3,091.2
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • In July 2025, we acquired all shares of Verve Therapeutics, Inc. (Verve) for a purchase price of $ 10.50 per share in cash (or an aggregate of approximately $ 549.4 million, net of cash acquired), plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $ 3.00 per share (or an aggregate of up to approximately $ 300 million) payable, subject to certain terms and conditions, upon the achievement of a certain specified milestone.
  • Our access to information was limited prior to this acquisition.
訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄閱讀原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Acquired in-process research and development (Note 3) 153.8 154.3 1,725.5 264.8
  • (1) As of June 30, 2025, there was $ 13.11 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
  • Acquired in-process research and development 1,725.5 264.8
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • In May 2024, we acquired NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC, which together own the assets of a manufacturing site in Wisconsin, for a purchase price of $ 924.7 million, net of cash acquired.
  • The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄閱讀原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Acquired in-process research and development (Note 3) 1,571.7 110.5
  • (1) As of March 31, 2025, there was $ 13.80 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
  • Acquired in-process research and development 1,571.7 110.5
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • Upon each asset acquisition, the cost allocated to acquired in-process research and development (IPR&D) was immediately expensed as acquired IPR&D if the compound had no alternative future use.
  • Milestone payment obligations incurred prior to regulatory approval of the compound were expensed as acquired IPR&D when the event triggering an obligation to pay the milestone occurred.
  • We recognized acquired IPR&D charges of $ 1.57 billion and $ 110.5 million for the three months ended March 31, 2025 and 2024, respectively.
  • The acquired IPR&D charges for the three months ended March 31, 2025 were primarily related to the acquisition of Scorpion Therapeutics, Inc.'s (Scorpion's) PI3Kα inhibitor program STX-478, currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.
  • We recognized no other significant acquired IPR&D charges during the three months ended March 31, 2025 and 2024.
訴訟進展 · 10-K 審閱文件原文 · 14 條摘錄閱讀原文 ↗
  • This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
  • We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.
  • business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."
  • In recent periods, we have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.
  • A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.
  • The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.
  • Some of our products are subject to significant license and collaboration agreements.
  • For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 4: Collaborations and Other Arrangements."
  • The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.
  • Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.

保險覆蓋範圍擴大(影響市場可及性)

僅有間接線索

資料截至 2026-09-30

已有與該變數相關的公司披露線索,但尚不能直接證明該變數,暫不輸出方向結論。

繼續關注:公司正式披露、可定位且與變數同口徑的經營 KPI

暫未列出足以直接回答此問題的依據。

檢視依據與尚未確認的問題

僅憑公司整體財務指標或行業敘事尚不能回答此問題。

間接線索 · 3 份檔案

客戶與供應鏈 · 10-Q 審閱文件原文 · 3 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
客戶與供應鏈 · 10-Q 審閱文件原文 · 4 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
客戶與供應鏈 · 10-Q 審閱文件原文 · 1 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

口服 GLP-1(Orforglipron)臨床進展(若成功將改變競爭格局)

僅有間接線索

資料截至 2026-09-30

已有與該變數相關的公司披露線索,但尚不能直接證明該變數,暫不輸出方向結論。

繼續關注:公司正式披露、可定位且與變數同口徑的經營 KPI

暫未列出足以直接回答此問題的依據。

檢視依據與尚未確認的問題

僅憑公司整體財務指標或行業敘事尚不能回答此問題。

間接線索 · 3 份檔案

客戶與供應鏈 · 10-Q 審閱文件原文 · 3 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
客戶與供應鏈 · 10-Q 審閱文件原文 · 4 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
客戶與供應鏈 · 10-Q 審閱文件原文 · 1 條摘錄閱讀原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

接下來檢查什麼

  1. Mounjaro + Zepbound 合計季度銷售額
  2. 全年收入指引是否上調
  3. 產能擴張里程碑(新工廠批准情況)
更新記錄與釋出資訊

資料期 2026-09-30 · 當前版本 2026-09-30.r1 · 本股釋出 2026-11-21

  1. 2026-10-29 · 資料期 2026-09-30 · 2026-09-30.r1

    納入截至 2026-09-30 的最新披露;0 個變數狀態發生變化。

  2. 2026-08-05 · 資料期 2026-06-30 · 2026-06-30.r1

    納入截至 2026-06-30 的最新披露;0 個變數狀態發生變化。

  3. 2026-04-30 · 資料期 2026-03-31 · 2026-03-31.r1

    Tracker 規則更新;底層披露期未變化,不視為新的投資邏輯版本。

全部原始資料 · 12 份檔案

同一份披露的摘錄集中展示;背景資料不等於研究問題的直接依據。

10-Q(提交於 2026-10-29) · 16 條摘錄閱讀原文 ↗
2026-09-30 · 2026 Q3:營收 24.40 十億美元,毛利率 83.88%,自由現金流 未披露。

SEC/XBRL 標準化欄位;資料質量分 86。

2026-09-30 · LLY 於 2026-10-29 提交 10-Q:截至 2026-09-30 的定期報告。

已審閱正文並提取 14 條結構化披露。 提取結果保留原文並單獨標註事實、展望或觀點。

2026-10-29 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · Acquired in-process research and development 4,181 656 7,541 2,381

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · Acquired in-process research and development 7,541 2,381

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · We have a license agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-29 · Acquisition date June 25, 2026 June 24, 2026 March 4, 2026

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

10-Q(提交於 2026-08-05) · 16 條摘錄閱讀原文 ↗
2026-06-30 · 2026 Q2:營收 22.97 十億美元,毛利率 85.78%,自由現金流 未披露。

SEC/XBRL 標準化欄位;資料質量分 86。

2026-06-30 · LLY 於 2026-08-05 提交 10-Q:截至 2026-06-30 的定期報告。

已審閱正文並提取 14 條結構化披露。 提取結果保留原文並單獨標註事實、展望或觀點。

2026-08-05 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · Acquired in-process research and development 2,776 154 3,360 1,726

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · Acquired in-process research and development 3,360 1,726

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-08-05 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

8-K 原始檔案 · 1 條摘錄閱讀原文 ↗
2026-10-29 · LLY 於 2026-10-29 提交 8-K:經營業績與財務狀況、財務報表與附件。

已審閱正文,未發現可由確定性規則結構化的重大經營訊號。 提取結果保留原文並單獨標註事實、展望或觀點。

SCHEDULE 13D 原始檔案 · 5 條摘錄閱讀原文 ↗
2026-10-16 · LLY 於 2026-10-16 提交 SCHEDULE 13D:股東行動。

已審閱正文並提取 4 條結構化披露。 提取結果保留原文並單獨標註事實、展望或觀點。

2026-10-16 · If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-16 · The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-16 · The funds used by the Reporting Person to acquire the Common Stock purchased in the IPO consisted of cash on hand.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-10-16 · The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

8-K 原始檔案 · 1 條摘錄閱讀原文 ↗
2026-08-05 · LLY 於 2026-08-05 提交 8-K:經營業績與財務狀況、財務報表與附件。

已審閱正文,未發現可由確定性規則結構化的重大經營訊號。 提取結果保留原文並單獨標註事實、展望或觀點。

併購交易 · SCHEDULE 13D 審閱文件原文 · 4 條摘錄閱讀原文 ↗
2026-07-30 · If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-07-30 · The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-07-30 · The funds used by the Reporting Person to acquire the Promissory Note and the Common Stock purchased in the IPO consisted of cash on hand.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-07-30 · The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.

按確定性規則從 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄閱讀原文 ↗
2026-04-30 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · As of March 31, 2026, we have the right to receive up to $ 660 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · In March 2026, we acquired all shares of Ventyx Biosciences, Inc. (Ventyx) for a purchase price of $ 14.00 per share in cash (or an aggregate of $ 1.1 billion, net of cash acquired).

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-04-30 · Our access to information was limited prior to this acquisition.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

訴訟進展 · 10-K 審閱文件原文 · 14 條摘錄閱讀原文 ↗
2026-02-12 · This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · See, for examples, Item 1A, "Risk Factors—Risks Related to Our Operations—Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could result in material harm to our business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · Some of our products are subject to significant license and collaboration agreements.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 3: Collaborations and Other Arrangements."

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2026-02-12 · For more information on patent challenges and litigation involving our intellectual property rights, see Item 1A, "Risk Factors—Risks Related to Our Intellectual Property—Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected" and Item 8, "Financial Statements and Supplementary Data—Note 16: Contingencies."

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄閱讀原文 ↗
2025-10-30 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · Acquired in-process research and development (Note 3) 655.7 2,826.4 2,381.2 3,091.2

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · (1) As of September 30, 2025, there was $ 12.40 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · Acquired in-process research and development 2,381.2 3,091.2

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · In July 2025, we acquired all shares of Verve Therapeutics, Inc. (Verve) for a purchase price of $ 10.50 per share in cash (or an aggregate of approximately $ 549.4 million, net of cash acquired), plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $ 3.00 per share (or an aggregate of up to approximately $ 300 million) payable, subject to certain terms and conditions, upon the achievement of a certain specified milestone.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-10-30 · Our access to information was limited prior to this acquisition.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄閱讀原文 ↗
2025-08-07 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · Acquired in-process research and development (Note 3) 153.8 154.3 1,725.5 264.8

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · (1) As of June 30, 2025, there was $ 13.11 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · Acquired in-process research and development 1,725.5 264.8

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · In May 2024, we acquired NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC, which together own the assets of a manufacturing site in Wisconsin, for a purchase price of $ 924.7 million, net of cash acquired.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-08-07 · The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄閱讀原文 ↗
2025-05-01 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · Acquired in-process research and development (Note 3) 1,571.7 110.5

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · (1) As of March 31, 2025, there was $ 13.80 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · Acquired in-process research and development 1,571.7 110.5

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · Upon each asset acquisition, the cost allocated to acquired in-process research and development (IPR&D) was immediately expensed as acquired IPR&D if the compound had no alternative future use.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · Milestone payment obligations incurred prior to regulatory approval of the compound were expensed as acquired IPR&D when the event triggering an obligation to pay the milestone occurred.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · We recognized acquired IPR&D charges of $ 1.57 billion and $ 110.5 million for the three months ended March 31, 2025 and 2024, respectively.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · The acquired IPR&D charges for the three months ended March 31, 2025 were primarily related to the acquisition of Scorpion Therapeutics, Inc.'s (Scorpion's) PI3Kα inhibitor program STX-478, currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-05-01 · We recognized no other significant acquired IPR&D charges during the three months ended March 31, 2025 and 2024.

按確定性規則從 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

訴訟進展 · 10-K 審閱文件原文 · 14 條摘錄閱讀原文 ↗
2025-02-19 · This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · In recent periods, we have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · Some of our products are subject to significant license and collaboration agreements.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 4: Collaborations and Other Arrangements."

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

2025-02-19 · Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.

按確定性規則從 SEC 10-K 正文或附件提取的原文片段,未由 AI 改寫;請結合上下文和公司原始檔案複核。

繼續關注這家公司

免費關注 LLY,方便下次繼續研究

通過郵件登入後,將公司加入自選,並選擇是否接收研究更新提醒。建立賬戶免費,不會自動扣費。

也可以使用 Google 或已有賬戶登入並關注。首次登入即建立免費賬戶。

加入自選方便下次繼續閱讀,郵件提醒需單獨訂閱。請留意各部分的報告期間,尚未確認的問題不代表已經發生。內容僅供研究參考,不構成投資建議。研究方法與限制

反饋